Literature DB >> 16700326

Hepatocyte transplantation in the Long Evans Cinnamon rat model of Wilson's disease.

Seon Mee Park1, Kim Vo, Michel Lallier, Alexis-Simon Cloutier, Pierre Brochu, Fernando Alvarez, Steven R Martin.   

Abstract

Wilson's disease (WD), caused by a mutation in the P-type copper transporting ATPase (Atp7b) gene, results in excessive accumulation of copper in the liver. Long Evans Cinnamon rats (LEC) bear a mutation in the atp7b gene and share clinical characteristics of human WD. To explore hepatocyte transplantation (HT) as therapy for metabolic liver diseases, 8-week-old LEC rats (n = 12) were transplanted by intrasplenic injection of hepatocytes from donor Long Evans (LE) rats. Immunosuppression was maintained with intraperitoneal tacrolimus. The success of HT was monitored at 24 weeks of life. Serum aminotransferases and bilirubin peaked at 14-21 weeks in both HT rats and nontransplanted controls, but at 24 weeks, survival was 97% in LEC-HT versus 63% in controls. All transplanted rats showed restored biliary copper excretion and reduced liver iron concentration associated with increased ceruloplasmin oxidase activity. Liver tissue expressed atp7b mRNA (11.9 +/- 13.6%) indicative of engraftment of normal cells in 7 of 12 HT rats, associated with a reduced liver copper concentration compared to untreated LEC rats. Periportal islets of normal appearing hepatocytes, recognized by atp7b antibody, were observed in transplanted livers while lobular host cells showed persistent pleomorphic changes and inflammatory infiltrates. In conclusion, transplantation of normal hepatocytes prevented fulminant hepatitis, reduces chronic inflammation, and improved 6-month survival in LEC rats. Engraftment of transplanted cells, which express atp7b mRNA, repopulated the recipient liver with normal functional capacity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16700326     DOI: 10.3727/000000006783982188

Source DB:  PubMed          Journal:  Cell Transplant        ISSN: 0963-6897            Impact factor:   4.064


  8 in total

Review 1.  Embryonic and induced pluripotent stem cells as a model for liver disease.

Authors:  Hiroshi Yagi; Edgar Tafaleng; Masaki Nagaya; Marc C Hansel; Stephen C Strom; Ira J Fox; Alejandro Soto-Gutierrez
Journal:  Crit Rev Biomed Eng       Date:  2009

Review 2.  Wilson's disease: update on integrated Chinese and Western medicine.

Authors:  Wen-Jie Li; Jun-Feng Wang; Xiao-Ping Wang
Journal:  Chin J Integr Med       Date:  2012-05-19       Impact factor: 1.978

Review 3.  Wilson disease-treatment perspectives.

Authors:  Tomasz Litwin; Karolina Dzieżyc; Anna Członkowska
Journal:  Ann Transl Med       Date:  2019-04

Review 4.  Therapeutic liver repopulation for phenylketonuria.

Authors:  Cary O Harding; K M Gibson
Journal:  J Inherit Metab Dis       Date:  2010-05-22       Impact factor: 4.982

5.  Menstrual blood-derived mesenchymal stem cells differentiate into functional hepatocyte-like cells.

Authors:  Xiao-zhou Mou; Jian Lin; Jin-yang Chen; Yi-fei Li; Xiao-xing Wu; Bing-yu Xiang; Cai-yun Li; Ju-ming Ma; Charlie Xiang
Journal:  J Zhejiang Univ Sci B       Date:  2013-11       Impact factor: 3.066

Review 6.  Therapeutic hepatocyte transplant for inherited metabolic disorders: functional considerations, recent outcomes and future prospects.

Authors:  Kara R Vogel; Andrew A Kennedy; Luke A Whitehouse; K Michael Gibson
Journal:  J Inherit Metab Dis       Date:  2013-10-02       Impact factor: 4.982

7.  Transplantation of ATP7B-transduced bone marrow mesenchymal stem cells decreases copper overload in rats.

Authors:  Shenglin Chen; Cunhua Shao; Tianfu Dong; Hao Chai; Xinkui Xiong; Daoyi Sun; Long Zhang; Yue Yu; Ping Wang; Feng Cheng
Journal:  PLoS One       Date:  2014-11-06       Impact factor: 3.240

8.  Iron metabolism is disturbed and anti-copper treatment improves but does not normalize iron metabolism in Wilson's disease.

Authors:  Grażyna Gromadzka; Diana Wierzbicka; Tomasz Litwin; Adam Przybyłkowski
Journal:  Biometals       Date:  2021-02-08       Impact factor: 2.949

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.